Stifel Maintains NOV Inc(NOV.US) With Buy Rating, Maintains Target Price $24
Barclays Maintains NOV Inc(NOV.US) With Sell Rating, Maintains Target Price $12
Piper Sandler Initiates NOV Inc(NOV.US) With Hold Rating, Announces Target Price $17
Barclays Maintains NOV Inc(NOV.US) With Sell Rating, Cuts Target Price to $12
NOV Is Maintained at Underweight by Barclays
Wells Fargo Reaffirms Their Sell Rating on NOV (NOV)
BMO Capital Initiates NOV Inc(NOV.US) With Hold Rating, Announces Target Price $18
NOV Analyst Ratings
ATB Capital Markets Initiates NOV Inc(NOV.US) With Hold Rating, Announces Target Price $19
Citi Maintains NOV Inc(NOV.US) With Hold Rating, Cuts Target Price to $17
NOV Downgraded at Citi as EBITDA Could Struggle to Grow in 2025
NOV Cut to Neutral From Buy by Citigroup
Citi Downgrades NOV Inc(NOV.US) to Hold Rating, Cuts Target Price to $18
NOV Is Maintained at Underweight by Wells Fargo
NOV Analyst Ratings
Wells Fargo Maintains NOV Inc(NOV.US) With Sell Rating, Cuts Target Price to $15
J.P. Morgan Maintains NOV Inc(NOV.US) With Buy Rating, Cuts Target Price to $20
NOV Price Target Cut to $21.00/Share From $22.00 by Susquehanna
NOV Is Maintained at Buy by Stifel
NOV Analyst Ratings